Research Article

The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity

Anastasiya M. Kaneva, Natalya N. Potolitsyna, Evgeny R. Bojko, and Jon Ø. Odland

1Institute of Physiology, Komi Science Center, Ural Branch of Russian Academy of Sciences, Pervomaiskaya Avenue 50, Syktyvkar 167982, Russia
2Faculty of Health Sciences, The Arctic University of Norway, 9037 Tromsø, Norway

Correspondence should be addressed to Anastasiya M. Kaneva; amkaneva@mail.ru

Received 25 November 2014; Revised 18 February 2015; Accepted 25 February 2015

1. Introduction

Atherosclerosis is a pathologic process affecting blood vessels, which leads to the development of cardiovascular disease [1, 2]. Although atherogenesis is a multifactorial process, abnormalities in lipid metabolism are a key factor, representing approximately 50% of the population-attributable risk of developing cardiovascular disease [3]. The recent studies have shown that using the conventional lipid indices can result in errors in the assessment of cardiovascular risk [4–6]. A considerable proportion of patients with atherosclerotic disease has levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) within the health-related reference interval [7, 8], and some patients who achieve significant LDL-C reduction with lipid-lowering therapy still develop cardiovascular disease [9, 10].

The main cause of errors in the estimation of the lipoprotein-related risk of cardiovascular disease when using the conventional lipid indexes is due to the wide variance of cholesterol within the low-density lipoprotein and high-density lipoprotein molecules; this variance is due to the active exchange of lipid components between lipoproteins. Hence, the lipoprotein cholesterol concentration does not always correspond to lipoprotein concentration [11, 12]. Unlike lipoprotein cholesterol, the lipid-transporting apolipoprotein (apo), apoB, remains with the lipoproteins without undergoing any changes [12]. ApoB is an essential structural component of very low-density lipoproteins, intermediate-density lipoproteins, and low-density lipoproteins. Because each particle of these lipoproteins contains one molecule of apoB, the total atherogenic particles number can be accurately estimated by measuring the plasma level of this apoprotein. In contrast, apoA-I, the major structural constituent of antiatherogenic high-density lipoproteins, exchanges between lipoproteins and the number of apoprotein molecules varies between lipoprotein particles.
Nevertheless, levels of apoA-I in plasma are strongly correlated with HDL levels. Therefore, apoB and apoA-I are assumed to be superior markers for lipoprotein abnormalities [11, 13–16]. The blood levels of apoA-I and apoB in patients with cardiovascular disease have been shown to be better discriminators than high-density lipoprotein cholesterol (HDL-C) and LDL-C levels [8, 17]. For example, in cases where LDL-C is in the health-related reference interval, high apoB levels may indicate an increased number of small, dense low-density lipoprotein particles, which are the most atherogenic particles [18–20].

Although the concentrations of apoB and apoA-I are associated with cardiovascular disease more strongly than the corresponding lipoprotein cholesterol fractions, the discriminant value of these apoproteins in absolute terms appears to be less than that of their ratio (the apoB/apoA-I ratio) [11]. The apoB/apoA-I ratio reflects the balance of atherogenic and antiatherogenic lipoproteins in plasma [4, 14–16]. Multiple clinical and epidemiological studies have confirmed that the apoB/apoA-I ratio is a superior marker for cardiovascular disease compared with lipids and lipoproteins or their ratios [2–4, 23–29]. Therefore, some studies demonstrated that the apoB/apoA-I ratio could discriminate between patients with coronary artery disease (CAD) and those without, even when the CAD patients had normal lipid levels [30]. The cut-off values for the apoB/apoA-I ratio that define a high cardiovascular risk were proposed to be 0.9 for men and 0.8 for women [14, 29].

In this study, we determined the variation limits of the apoB/apoA-I ratio in healthy middle-aged men with normolipidemia and the relationship of this ratio with other lipid indexes.

2. Materials and Methods

2.1. Subjects and Sampling. Our study included 157 apparently healthy men with normolipidemia. Anthropometric measurements (height and weight) and other personal information were obtained during the clinical examination and the interview. Weight was measured to the nearest 100 g using a standard medical scale while the subjects were minimally clothed without shoes. Height was measured to the nearest 0.5 cm in a standing position without shoes using a standard stadiometer. The body mass index was calculated as the weight (in kilograms) divided by the square of the height (in meters).

Participants were excluded from the study using the following criteria: (i) a body mass index of 30 kg/m² or greater; (ii) a TC concentration above 5.2 mmol/L; (iii) a triglycerides (TG) concentration above 1.8 mmol/L; and (iv) a HDL-C concentration below 0.9 mmol/L. All participants were considered to be free from serious and chronic illnesses at the time of the recruitment. Each subject gave written informed consent for participating in the study, which was approved by the Ethics Committee of Institute of Physiology, Komi Science Center, Ural Branch of Russian Academy of Sciences.

Fasting blood samples were taken from the antecubital vein into vacutainers (Becton Dickinson BP). Blood samples were centrifuged and plasma was placed into Eppendorf microcentrifuge tubes and was stored at −40°C until analysis.

2.2. Lipid Measurements. The plasma TC and TG concentrations were measured using an enzymatic method with commercially available kits (Chronolab Systems, S.L. Barcelona, Spain). The HDL-C concentration was determined by assaying the cholesterol in the supernatant obtained after the precipitation of apoB-containing lipoproteins with phosphotungstate/magnesium chloride. The plasma apoA-I, apoB, and apoE concentrations were measured using an immunoturbidimetric method with kits (Chronolab Systems, S.L. Barcelona, Spain). The samples were analyzed immediately after thawing at 37°C in a thermostatic bath. The measurement of each sample was carried out in duplicate, and the mean was calculated. The absorbance of all samples was measured on the PowerWave 200 automated spectrophotometer (BioTek Instruments, USA).

The LDL-C was calculated according to Friedewald’s formula [31]. The non-HDL-C was calculated as the difference between the TC and HDL-C. Some clinical indicators of lipids metabolism were computed, including the TC/HDL-C, apoB/apoA-I, and LDL-C/apoB ratios, as well as atherogenic index of plasma (AIP).

For calculating the LDL-C/apoB ratio, the concentration of LDL-C is transformed of mmol/L in mg/dL. AIP was calculated as a logarithm of the ratio of the molar concentration (mmol/L) of TG to HDL-C (i.e., log [TG/HDL-C]) [32].

2.3. Statistical Analysis. The statistical analysis was performed using Statistica 6.0 (Statsoft, Tulsa, USA). The continuous variables in the tables are presented as the median and interquartile range (25th and 75th percentiles). Differences between the groups were analyzed using the Mann-Whitney test and the chi-squared test. Correlations between the indices were assessed using the Spearman’s rank correlation. A value of $P < 0.05$ was accepted as statistically significant.

3. Results

The main characteristics of the studied subjects are shown in Table 1. The subjects ranged in age from 20 to 59 years with the average age of 36.0 years. The median for body mass index in the studied men was 24.8 kg/m².

The median value (25%; 75%) of the apoB/apoA-I ratio for the entire group was 0.52 (0.42; 0.78), with values ranging from 0.19 to 2.60. By virtue of the exclusion criteria, the plasma TC, TG, and HDL-C levels in the men varied in the health-related reference interval. Nevertheless, of the 157 studied subjects, 30 men (19.1%) had the apoB/apoA-I ratio above 0.9. The values of apoB and apoA-I varied from 30.0 to 218.0 mg/dL and from 50.0 to 300.0 mg/dL, respectively. According to the health-related reference values of apoproteins [21, 22], low values of apoA-I were determined in 14 subjects, and high values of apoB were found in 9 men of 30 subjects with the unfavourable apoB/apoA-I ratio. Seven subjects had low levels of apoA-I along with high levels of apoB. In the group of men with apoB/apoA-I < 0.9, low values of apoA-I and high values of apoB were observed in 33 and
Table 1: Baseline characteristics of study participants (n = 157).

|                   | Median (25%; 75%) | Min–Max |
|-------------------|-------------------|---------|
| Age, years        | 36.0 (29.0; 45.0) | 20–59   |
| Body mass index, kg/m² | 24.8 (22.6; 26.5) | 18.0–29.9 |
| TC, mmol/L        | 4.13 (3.58; 4.64) | 2.73–5.15 |
| TG, mmol/L        | 1.11 (0.87; 1.38) | 0.56–1.70 |
| HDL-C, mmol/L     | 1.40 (1.21; 1.56) | 1.00–1.99 |
| LDL-C, mmol/L     | 2.21 (1.66; 2.69) | 0.42–3.68 |
| Non-HDL-C, mmol/L | 2.74 (2.14; 3.26) | 1.01–4.11 |
| TC/HDL-C          | 2.93 (2.48; 3.45) | 1.57–4.99 |
| ApoA-I, mg/dL     | 149.8 (100.8; 180.0) | 50.0–300.0 |
| ApoB, mg/dL       | 78.0 (56.1; 102.0) | 30.0–218.0 |
| ApoB/apoA-I       | 0.52 (0.42; 0.78) | 0.19–2.60 |
| ApoE, mg/dL       | 2.61 (1.91; 3.46) | 0.48–5.54 |
| LDL-C/C/apoB      | 1.06 (0.73; 1.46) | 0.20–2.48 |
| AIP               | −0.09 (−0.22; −0.01) | −0.45–0.22 |

Values are presented as the median, interquartile range, minimum, and maximum.

5 subjects (26.0% and 3.1% of the total cases), respectively (Figure 1).

Table 2 compares the subjects with apoB/apoA-I <0.9 with those with apoB/apoA-I >0.9. There were expected differences (due to the way in which the study was designed) between the groups in their apoB and apoA-I levels and the ratios in which the apoproteins were used as components. The group of the subjects with apoB/apoA-I >0.9 was characterized by higher TG levels (+27.6%; P = 0.004) and AIP (+50.0%; P = 0.032) and lower apoE levels (−22.1%; P = 0.011) compared to the group of the men with apoB/apoA-I <0.9 (Table 2). The TC, HDL-C, LDL-C, non-HDL-C levels, and TC/HDL-C ratio did not significantly differ between the two groups. Nevertheless, of note, the subjects with the high apoB/apoA-I ratio were more likely to have an atherogenic lipid profile. Reduced levels of apoA-I in the men with the unfavourable apoB/apoA-I ratio against the background of invariable concentration of HDL-C may indicate a decline of the functional properties of high-density lipoproteins. A significant decrease of the LDL-C/C/apoB ratio in the subjects with apoB/apoA-I >0.9 (compared with those with apoB/apoA-I <0.9) reflected the presence of small, dense low-density lipoprotein particles.

Using Spearman’s rank correlation (Table 3), TG, apoE, and AIP were found to be significantly correlated with the apoB/apoA-I ratio. No correlation was observed between the apoB/apoA-I ratio and the levels of TC, HDL-C, LDL-C, and non-HDL-C or TC/HDL-C ratio. ApoA-I did not reveal a significant positive or negative correlation with any lipid parameters. As expected, the plasma levels of apoB were positively associated with the TC, TG, and non-HDL-C levels, as well as the TC/HDL-C ratio and AIP. A significant negative correlation was also observed between apoB and apoE.

The relationship between the values of the apoB/apoA-I ratio and the plasma apoE levels was evaluated using the stratification of the subjects according to the quartiles of apoE levels, as well as the apoB/apoA-I ratio values that have been proposed to define increased cardiovascular risk (cut-off values >0.9) (Figure 2). The unfavourable apoB/apoA-I ratio was more frequently observed in the subjects with the low levels of apoE (1st and 2nd quartiles). The percentage of the subjects with apoB/apoA-I >0.9 decreased significantly with the progressive increase in apoE levels (χ² = 8.20; P = 0.042). In particular, in the 1st and 2nd quartiles, these percentages were 28.2% and 27.5%, respectively; in the 3rd and 4th quartiles, they decreased to 7.7% and 12.8%, respectively.

4. Discussion

The atherogenic lipid profile is an important risk factor for cardiovascular disease. This profile is characterized by elevated levels of TC, LDL-C, and TG and lowered levels of HDL-C [33, 34]. However, these traditional lipid risk factors are not always adequate indicators of cardiovascular risk [35]. The most recent studies have shown that the diagnostic accuracy of the apoB/apoA-I ratio is significantly greater than that of any lipid parameters [2–4, 23–29].

A total of 19.1% of the studied subjects with normolipidemia had the apoB/apoA-I ratio that exceeded 0.9. The epidemiological studies have revealed that a higher apoB/apoA-I ratio indicates a higher cardiovascular risk, such that the cut-off value of 0.9 has been proposed to define a risk of developing cardiovascular disease [14]. Thus, our results have shown that the unfavourable values of the apoB/apoA-I ratio

Table 2: The plasma lipids and apolipoproteins in the groups with apoB/apoA-I <0.9 (n = 127) and apoB/apoA-I >0.9 (n = 30).

|                   | Group with apoB/apoA-I <0.9 | Group with apoB/apoA-I >0.9 | P value* |
|-------------------|----------------------------|-----------------------------|---------|
| Age, years        | 35.0 (29.0; 43.0)          | 39.0 (30.0; 47.0)           | 0.185   |
| Body mass index, kg/m² | 24.7 (22.7; 26.5)          | 24.8 (21.9; 25.7)           | 0.813   |
| TC, mmol/L        | 4.12 (3.55; 4.64)          | 4.24 (3.58; 4.73)           | 0.825   |
| TG, mmol/L        | 1.05 (0.85; 1.34)          | 1.34 (1.06; 1.65)           | 0.004   |
| HDL-C, mmol/L     | 1.40 (1.21; 1.55)          | 1.41 (1.25; 1.58)           | 0.420   |
| LDL-C, mmol/L     | 2.30 (1.66; 2.70)          | 2.10 (1.60; 2.64)           | 0.478   |
| Non-HDL-C, mmol/L | 2.74 (2.14; 3.26)          | 2.71 (2.06; 3.28)           | 0.943   |
| TC/HDL-C          | 2.93 (2.50; 3.51)          | 2.92 (2.36; 3.25)           | 0.538   |
| ApoA-I, mg/dL     | 152.6 (115.0; 188.0)       | 102.6 (73.0; 122.4)         | <0.001  |
| ApoB, mg/dL       | 71.0 (53.0; 89.0)          | 147.9 (98.9; 190.0)         | <0.001  |
| ApoB/apoA-I       | 0.48 (0.38; 0.62)          | 1.36 (1.07; 1.61)           | <0.001  |
| ApoE, mg/dL       | 2.81 (2.00; 3.55)          | 2.19 (1.23; 2.96)           | <0.011  |
| LDL-C/C/apoB      | 1.16 (0.88; 1.59)          | 0.61 (0.43; 0.69)           | <0.001  |
| AIP               | −0.10 (−0.23; −0.01)       | −0.05 (−0.15; 0.04)         | 0.032   |

Values are presented as the median and interquartile range. *The Mann-Whitney U test was used to estimate differences between the groups.
Table 3: Spearman correlation coefficients between the apoA-I, apoB, apoB/apoA-I ratio, and other lipid parameters (n = 157).

|            | ApoA-I | ApoB | ApoB/apoA-I ratio |
|------------|--------|------|-------------------|
|            | Spearman, r | P-level | Spearman, r | P-level | Spearman, r | P-level |
| TC         | 0.06   | 0.443 | 0.17    | 0.031   | 0.06    | 0.421   |
| TG         | -0.04  | 0.577 | 0.41    | <0.001  | 0.32    | <0.001  |
| HDL-C      | 0.07   | 0.335 | -0.06   | 0.426   | -0.07   | 0.362   |
| LDL-C      | 0.08   | 0.301 | 0.12    | 0.125   | 0.04    | 0.655   |
| Non-HDL-C  | 0.08   | 0.312 | 0.21    | 0.010   | 0.09    | 0.240   |
| TC/HDL-C   | 0.08   | 0.302 | 0.21    | 0.009   | 0.12    | 0.139   |
| ApoE       | -0.01  | 0.867 | -0.28   | <0.001  | -0.19   | 0.012   |
| AIP        | -0.02  | 0.797 | 0.42    | <0.001  | 0.33    | <0.001  |

Data are correlation coefficients and P values. The Spearman’s rank correlation was used.

Figure 1: Distribution of subjects depending on the apoA-I and apoB levels in the groups with apoB/apoA-I <0.9 and apoB/apoA-I >0.9. Values of apoB >120 mg/dL and apoA-I <120 mg/dL have been proposed as the cut-off points defining a high cardiovascular risk [21, 22].

may be observed in subjects without atherogenic changes in their lipid profile. Similar data have been reported by other authors [36–39]. The results of these clinical cross-sectional and prospective studies have shown that the apoB/apoA-I ratio was the only lipid-related variable that differentiated normolipidemic patients with CAD from those without CAD.

The lipoprotein-related risk is associated with the overall balance between the atherogenic and antiatherogenic lipoproteins. Several lipoprotein and apoprotein ratios or “atherogenic indices” have been defined to express this balance. The TC/HDL-C, apoB/apoA-I, and AIP are the most well-known ratios indicating the balance between the atherogenic and protective lipoproteins [35]. In the studied subjects, the apoB/apoA-I ratio was correlated with AIP. However, no relationship was found between the apoB/apoA-I and TC/HDL-C ratios. It is believed that the TC/HDL-C ratio indicates the proportion of atherogenic to antiatherogenic lipoproteins. However, the cholesterol levels in lipoproteins do not always accurately reflect the concentrations of the plasma lipoproteins. This may occur during changes in the size and composition of the lipoprotein particles [4]. The absence of correlation between the apoB/apoA-I and TC/HDL-C ratios in the studied subjects indicates a difference in the predictive power of these ratios. At the same time, the significant positive correlation between the apoB/apoA-I ratio and AIP was found. AIP, calculated as log [TG/HDL-C], reflects the balance between atherogenic and protective lipoproteins and theoretically depicts the high-density lipoproteins esterification rate and low-density lipoproteins size. High AIP indicates an increase in the percentage of small high-density lipoproteins and small, dense low-density lipoprotein particles in plasma [32]. Thus,
ApoB/apoA-I ratio by raising the LDL-C levels. A sar e sult, the LDL-apoB/apoA-I lipolysis, leading to hypertriglyceridemia [43, 44]. We have previously shown that the low apoE levels may contribute to hypertriglyceridemia in residents of the European North of Russia [45]. The results of the present study have indicated a relationship between the unfavourable apoB/apoA-I ratio and the low plasma apoE levels (Figure 2). Moreover, the significant negative correlation between apoE and apoB was found (Table 3). Thus, an increase in the apoB/apoA-I ratio in the studied subjects may be assumed to be accompanied by the accumulation of TG-rich lipoproteins in plasma, which was associated with the reduced plasma very low-density lipoproteins clearance due to the low levels of apoE.

5. Conclusions

The apoB/apoA-I ratio exceeding 0.9 may be observed even in the subjects with normolipidemia. An increase in the apoB/apoA-I ratio was accompanied by a rise of AIP, which indicated simultaneous changes in the number and composition of lipoproteins in the studied subjects. The subjects with apoB/apoA-I > 0.9 were also characterized by higher levels of TG and lower values of LDL-C/apoB ratio and concentrations of apoE compared with the subjects with apoB/apoA-I < 0.9. On the whole, the subjects with apoB/apoA-I > 0.9 had more atherogenic lipid profile. Thus, the apoB/apoA-I ratio can be considered as a sensitive marker of atherogenic risk.

Abbreviations

Apo: Apolipoprotein
AIP: Atherogenic index of plasma
CAD: Coronary artery disease
HDL-C: High-density lipoprotein cholesterol
LDL-C: Low-density lipoprotein cholesterol
TC: Total cholesterol
TG: Triglycerides.

Conflict of Interests

The authors declare that they have no competing interests.

Acknowledgment

The study is supported by Program of UD RAS, Project no. 15-3-4-19.

References

[1] Y. Sherer and Y. Shoenfeld, “Mechanisms of disease: atherosclerosis in autoimmune diseases,” Nature Clinical Practice Rheumatology, vol. 2, no. 2, pp. 99–106, 2006.

[2] C. Schmidt, B. Fagerberg, J. Wikstrand, and J. Hulthe, “ApoB/apoA-I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men,” Atherosclerosis, vol. 189, no. 1, pp. 178–185, 2006.

[3] S. Yusuf, S. Hawken, S. Ounpuu et al., “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.” The Lancet, vol. 364, no. 9438, pp. 937–952, 2004.
[4] A. D. Sniderman, I. Junger, I. Holme, A. Aastveit, and G. Walldius, “Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease,” *Journal of Internal Medicine*, vol. 259, no. 5, pp. 455–461, 2006.

[5] G. Walldius, I. Junger, A. H. Aastveit, I. Holme, C. D. Furberg, and A. D. Sniderman, “The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk,” *Clinical Chemistry and Laboratory Medicine*, vol. 42, no. 12, pp. 1355–1363, 2004.

[6] L. Johansson and C. Schmidt, “Increased apoB/apoA-I ratio is predictive of peripheral arterial disease in initially healthy 58-year-old men during 8.9 years of follow-up,” *Angiology*, vol. 60, no. 5, pp. 539–545, 2009.

[7] G. S. Ginsburg, C. Safran, and R. C. Pasternak, “Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with ‘desirable’ total cholesterol levels,” *The American Journal of Cardiology*, vol. 68, no. 2, pp. 187–192, 1991.

[8] J. Genest Jr., J. R. McNamara, J. M. Ordovas et al., “Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease,” *Journal of the American College of Cardiology*, vol. 19, no. 4, pp. 792–802, 1992.

[9] H. R. Superko, “Beyond LDL cholesterol reduction,” *Circulation*, vol. 94, no. 10, pp. 2351–2354, 1996.

[10] J. E. R. van Lennep, H. T. Westerveld, H. W. O. R. van Lennep, A. H. Zwinderman, D. W. Erkelens, and E. E. van der Wall, “Apolipoprotein concentrations during treatment and recurrent coronary artery disease events,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 20, no. 11, pp. 2408–2413, 2000.

[11] S. R. Srinivasan and G. S. Berenson, “Serum apolipoproteins A-I and B as markers of coronary artery disease risk in early life: the Bogalusa Heart Study,” *Clinical Chemistry*, vol. 41, no. 1, pp. 159–164, 1995.

[12] A. D. Sniderman, T. Pedersen, and J. Kjekshus, “Putting low-density lipoproteins at center stage in atherogenesis,” *The American Journal of Cardiology*, vol. 79, no. 1, pp. 64–67, 1997.

[13] J. Elovson, J. E. Chatterton, G. T. Bell et al., “Plasma very low density lipoproteins contain a single molecule of apolipoprotein B,” *Journal of Lipid Research*, vol. 29, no. 11, pp. 1461–1473, 1988.

[14] G. Walldius and I. Junger, “Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy,” *Journal of Internal Medicine*, vol. 255, no. 2, pp. 188–205, 2004.

[15] G. Walldius, “The apoB/apoA-I ratio is a strong predictor of cardiovascular risk,” in *Lipoproteins in Health and Diseases*, S. Frank and G. Kostner, Eds., pp. 95–148, InTech, Rijeka, Croatia, 2012.

[16] A. Thompson and J. Danesh, “Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies,” *Journal of Internal Medicine*, vol. 259, no. 5, pp. 481–492, 2006.

[17] M. S. Graziani, L. Zanolla, G. Righetti, C. Marchetti, P. Mocarelli, and S. M. Marcovina, “Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group,” *Clinical Chemistry*, vol. 44, no. 1, pp. 134–140, 1998.

[18] A. Sniderman, S. Shapiro, D. Marpole, B. Skinner, B. Teng, and P. O. Kwiterovich Jr., “Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (β) lipoproteins],” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 77, no. 1, pp. 604–608, 1980.

[19] J. R. Crouse, J. S. Parks, H. M. Schey, and F. R. Kahl, “Studies of low density lipoprotein molecular weight in human beings with coronary artery disease,” *Journal of Lipid Research*, vol. 26, no. 5, pp. 566–574, 1985.

[20] M. A. Austin, J. L. Breslow, C. H. Hennekens, J. E. Buring, W. C. Willett, and R. M. Krauss, “Low-density lipoprotein subclass patterns and risk of myocardial infarction,” *The Journal of the American Medical Association*, vol. 260, no. 13, pp. 1917–1921, 1988.

[21] J. H. Contois, J. R. McNamara, C. J. Lammi-Keefe, P. W. F. Wilson, T. Massov, and E. J. Schaefer, “Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study,” *Clinical Chemistry*, vol. 42, no. 4, pp. 515–523, 1996.

[22] J. H. Contois, J. R. McNamara, C. J. Lammi-Keefe, P. W. F. Wilson, T. Massov, and E. J. Schaefer, “Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study,” *Clinical Chemistry*, vol. 42, no. 4, pp. 507–514, 1996.

[23] G. Walldius, I. Junger, I. Holme, A. H. Aastveit, W. Kolar, and E. Steiner, “High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study,” in *The Lancet*, vol. 358, no. 9298, pp. 2026–2033, 2001.

[24] P. J. Talmud, E. Hawe, G. J. Miller, and S. E. Humphries, “Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men,” *Atherosclerosis, Thrombosis, and Vascular Biology*, vol. 22, no. 11, pp. 1918–1923, 2002.

[25] K. Dunder, L. Lind, B. Zethelius, L. Berglund, and H. Lithell, “Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein AI ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM),” *The American Heart Journal*, vol. 148, no. 4, pp. 596–601, 2004.

[26] L. Lind, B. Vessby, and J. Sundström, “The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men,” *Atherosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 2, pp. 406–410, 2006.

[27] W. A. van der Steeg, S. M. Boekholdt, E. A. Stein et al., “Role of the apolipoprotein B/apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk,” *Annals of Internal Medicine*, vol. 146, no. 9, pp. 640–648, 2007.

[28] M. J. McQueen, S. Hawken, X. Wang et al., “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEARTstudy): a case–control study,” *The Lancet*, vol. 372, no. 9634, pp. 224–233, 2008.

[29] G. P. C. Schianca, R. Pedrazzoli, S. Onolfo et al., “ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk,” *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 21, no. 6, pp. 406–411, 2011.

[30] G. Walldius and I. Junger, “The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence,” *Journal of Internal Medicine*, vol. 259, no. 5, pp. 493–519, 2006.
[31] W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972.

[32] M. Dobíšová and J. Frohlich, “The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER_{HDL}),” Clinical Biochemistry, vol. 34, no. 7, pp. 583–588, 2001.

[33] W. B. Kannel, W. P. Castelli, T. Gordon, and P. M. McNamara, “Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study,” Annals of Internal Medicine, vol. 74, no. 1, pp. 1–12, 1971.

[34] S. M. Grundy, D. Bilheimer, A. Chait et al., “Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II),” Journal of the American Medical Association, vol. 269, no. 23, pp. 3015–3023, 1993.

[35] J. Millán, X. Pintó, A. Muñoz et al., “Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention,” Vascular Health and Risk Management, vol. 5, pp. 757–765, 2009.

[36] H. T. Westerveld, J. E. van Roeters Lennep, H. W. O. van Roeters Lennep et al., “Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 7, pp. 1101–1107, 1998.

[37] M. Haidari, M. Moghadam, M. Chinicar, A. Ahmadieh, and M. Doosti, “Apolipoprotein B as the best predictor of coronary artery disease in Iranian normolipidemic patients,” Clinical Biochemistry, vol. 34, no. 2, pp. 149–155, 2001.

[38] C. Snehalatha, A. Ramachandran, S. Sivasankari et al., “Is increased apolipoprotein B-A major factor enhancing the risk of coronary artery disease in type 2 diabetes?” Journal of Association of Physicians of India, vol. 50, no. 8, pp. 1036–1038, 2002.

[39] H.-K. Kim, S.-A. Chang, E.-K. Choi et al., “Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population,” International Journal of Cardiology, vol. 101, no. 3, pp. 435–440, 2005.

[40] A. M. Wagner, O. Jorba, M. Rigla, E. Alonso, J. Ordóñez-Llanos, and A. Pérez, “LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes,” Acta Diabetologica, vol. 39, no. 4, pp. 215–220, 2002.

[41] S. Marcovina and C. J. Packard, “Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels,” Journal of Internal Medicine, vol. 259, no. 5, pp. 437–446, 2006.

[42] N. F. Galeano, M. Al-Haideri, F. Keyserman, S. C. Rumsey, and R. J. Deckelbaum, “Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity,” Journal of Lipid Research, vol. 39, no. 6, pp. 1263–1273, 1998.

[43] R. W. Mahley, K. H. Weisgraber, and Y. Huang, “Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS,” Journal of Lipid Research, vol. 50, supplement, pp. S183–S188, 2009.

[44] A. M. Kaneva, E. R. Boiko, N. N. Potolitsyna, and J. O. Odland, “Plasma levels of apolipoprotein-E in residents of the European North of Russia,” Lipids in Health and Disease, vol. 12, no. 1, article 43, 2013.

[45] E. R. Boiko, A. M. Kaneva, and N. N. Potolitsyna, “Functional importance of apolipoprotein-E in lipid metabolism in inhabitants of the European North,” Fiziologiya Cheloveka, vol. 36, no. 2, pp. 138–144, 2010.